TAIPEI, Taiwan May 16, 2024 – ImmunAdd, a privately held company developing a fully synthetic saponin-based small molecule, attended to WVC Washington during 4/2~4/4. ImmunAdd is a group of scientists with extensive knowledge of medical chemistry, drug formulation, drug regulations, biological animal evaluation, and clinical trials, and is working on developing drugs for infectious disease, cancer therapy, and immunotherapies.

“We are excited to attend WVC and provide an update on the innovative vaccine adjuvant research being conducted at ImmunAdd.”, said by Dr. Pi-Hui Liang, Founder and CEO at ImmunAdd Inc..

ImmunAdd, Inc. is a privately held biopharmaceutical company which was founded in 2022 on a mission to improve health through advances in vaccine adjuvants, new formulation, and new drug design. The company is developing next generation saponin adjuvants, new combination of adjuvants and adjuvanted vaccines.

“Innovation for Better Health”

We are ImmunAdd.